siRNAs block the expression of specific genes with complementary nucleotide sequences by selectively silencing the translation of their complementary target mRNAs. The use of small interfering RNA (siRNA) represents another strategy to reduce PCSK9 secretion. We also discuss the new alternative therapies for the treatment of dyslipidemia and their relevance to practice. This narrative review provides an overview of the new drugs for the treatment of dyslipidemia, their current status, ongoing clinical or preclinical trials, and their prospects. Recently, however, new and promising pharmacological strategies have become available. These patients respond poorly to conventional therapies. Familial hypercholesterolemia (FH) can lead to CVD early in life. Triglycerides also play an important role in the development of CVD new therapeutic approaches are also very promising for their treatment. Recently, several new cholesterol-lowering drugs have been developed and approved others are promising results, enriching the pharmacological armamentarium beyond statins. Combining statins with different therapeutic approaches and testing other new drugs is the future key to reducing the burden of cardiovascular disease (CVD). However, some patients do not reach optimal LDL-C target levels or do not tolerate statins, especially when taking high doses long-term.
Statin therapy is the standard treatment for lowering LDL-C in primary and secondary prevention.
Low-density lipoprotein cholesterol (LDL-C) plays a crucial role in the development of atherosclerosis.
0 kommentar(er)
